Edison Research values IMU at 4.1c, page-7

LC has been involved in 300+ trials, the Profs in Vienna and Ohio are vaxx developing experts and AH as well as PH have the business side covered, so what ever number of patients they recruited and will recruit will be sufficient for the relevant trial stages. They know what pharma wants and needs to make decisions, l think we can rest assured they chose the optimal
trial conditions.

It is a new tech and approach to fight and prevent cancer and due to the published exciting results and the current FOMO displayed by US pharmas, the usual deal making criteria may not apply and early stage deals are more likely.

We just have read about acting US giants, what about the European, Russian, Asian and Middle East giants? 

I am convinced we will be pleasantly
surprised sooner than we think.

Thanks to all posters, each post helps to spread the word and to educate newbees.

GLTA